Macrophage Pharma is an immuno-oncology company focussed on the discovery and development of novel therapies designed to enhance anti-tumour immune responses.

Macrophage Pharma’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.

Macrophage Pharma’s novel Esterase Sensitive Motif™ (ESM™) technology has delivered agents which are being developed to induce targeted and durable anti-tumour immune responses and provide next-generation immunotherapy with broad utility in oncology.

Macrophage Pharma’s approach is to create a more hostile environment for tumour growth by:

• Reprogramming tumour macrophages to stimulate the anti-tumour immune response
• Reversing immunosuppression in the tumour microenvironment
• Converting tolerogenic dendritic cells to effective antigen presenting cells

The company is exploiting a unique and proprietary knowledge base to unleash the full therapeutic potential of ESM technology in immuno-oncology.